PCPeer Christiansen

Peer Christiansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peer Christiansen has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Bent Ejlertsen

    Department of Oncology, Rigshospitalet, Copenhagen University Hospital; DBCG-secretariat, Department 2501, Rigshospitalet, Copenhagen Ø, Denmark

    2 shared publications
  • Maj-Britt Jensen

    DBCG-secretariat, Department 2501, Rigshospitalet, Copenhagen Ø, Denmark

    2 shared publications
  • Niels Kroman

    Department of Breast Surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

    2 shared publications
  • Susanne Møller

    DBCG Data Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

    2 shared publications
  • A.-V. Laenkholm

    1 shared publication
  • Alma Becic Pedersen

    Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

    1 shared publication

Latest Publications

  • Open Access

    Breast-Conserving Surgery or Mastectomy?

    by Peer Md Christiansen, Marco Mele, Anne Bodilsen, Nicola Rocco, Robert Dmsc Zachariae

    Introduction: The early randomized controlled trials revealed no differences in survival between breast-conserving surgery (BCS) and mastectomy. However, breast cancer treatment has undergone changes, and the results of recent population-based registry studies suggest superior long-term survival after BCS. To explore the current evidence, a systematic review and meta-ana lysis of population-based observational studies from 2010 and onward was conducted. Methods: A literature search was conducted in the PubMed, Embase, and Cochrane databases to identify relevant literature. Keywords included “mastectomy,” “breast conserving surgery,” and “survival.” The identified studies were narratively reviewed and effect sizes (hazard ratios [HRs]) for overall (OS) and breast cancer-specific survival (BCSS) were combined with random-effects models. Results: A total of 30 reports were included in the review, and results from 25 studies were included in the meta-analyses. Compared with mastectomy, BCS was associated with better OS (HR = 1.34 [1.20–1.51]; N = 1,311,600) and BCSS (HR = 1.38 [1.29–1.47]; N = 494,267). Selected subgroups of patients, based on lymph node status, age (<50 years/≥50 years), and radiation therapy after mastectomy (±), all showed better overall survival after BCS. The number (range 4–12) and type of prognostic variables adjusted for in the survival analyses of the studies did not statistically significantly moderate the differences in survival between BCS and mastectomy. Conclusions: The combined findings from large population-based studies indicate that BCS is associated with survival benefit compared with mastectomy, suggesting that BCS be the recommended treatment of early breast cancer (T1-2N0-1M0) if a radical lumpectomy can be performed.


  • Anaplastic thyroid carcinoma in Denmark 1996–2012: A national prospective study of 219 patients

    by Gitte Bjørn Hvilsom, Stefano Christian Londero, Christoffer Holst Hahn, Sten Schytte, Henrik Baymler Pedersen, Peer Christiansen, Katalin Kiss, Stine Rosenkilde Larsen, Marie Louise Jespersen, Giedrius Lelkaitis, et al.


  • Open Access

    Use of prescription drugs and risk of postoperative red blood cell transfusion in breast cancer patients: a Danish population-based cohort study

    by Anne Marie L. Thomsen, Alma B. Pedersen, Nickolaj R. Kristensen, Bjarne Kuno Møller, Christian Erikstrup, Peer M. Christiansen, Mette Nørgaard, Deirdre Cronin-Fenton

    Several frequently used prescription drugs may affect bleeding risk. We investigated use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), selective serotonin reuptake inhibitors (SSRIs), and statins and risk of postoperative red blood cell transfusion in breast cancer patients. Using Danish population-based registries, we identified a cohort of women who underwent surgery for primary breast cancer (n = 22,238) during 2005–2012 and ascertained their use of aspirin, NSAIDs, SSRIs, and statins. For each drug, patients were categorized as users if they filled ≥1 prescription in the 60 days prior to surgery. We calculated the 14-day risk of red blood cell transfusion and relative risks (RRs) with 95% confidence intervals (CIs), comparing users with nonusers for each drug and adjusting for age, cancer stage, and Charlson Comorbidity Index score. In our cohort, 1385 (6.2%) women were aspirin users, 1794 (8.0%) were NSAID users, 1110 (4.9%) were SSRI users, and 2053 (9.1%) were statin users. The overall risk of red blood cell transfusion was 1.3%. The 14-day risk of RBC transfusion was 3.5% among aspirin users versus 1.1% among aspirin nonusers (adjusted RR = 1.9, 95% CI: 1.4–2.7), and 1.8% among SSRI users versus 1.2% among SSRI nonusers (adjusted RR = 1.2, 95% CI: 0.7–1.9). Red blood cell transfusion risk was increased among NSAID users, but not in a sensitivity analysis with a 30-day exposure window. Red blood cell transfusion risk was not increased among SSRI and statin users. Primary breast cancer surgery confers a low risk of RBC transfusion. Still, use of aspirin and possibly NSAIDs, but not SSRIs and statins, is associated with increased red blood cell transfusion. This increased risk is not explained by differences in age, stage, or comorbidity level.


  • Open Access

    Danish Breast Cancer Cooperative Group

    by Peer Christiansen, Bent Ejlertsen, Maj-Britt Jensen, Henning Mouridsen

    Aim of database: Danish Breast Cancer Cooperative Group (DBCG), with an associated database, was introduced as a nationwide multidisciplinary group in 1977 with the ultimate aim to improve the prognosis in breast cancer. Since then, the database has registered women diagnosed with primary invasive nonmetastatic breast cancer. The data reported from the departments to the database included details of the characteristics of the primary tumor, of surgery, radiotherapy, and systemic therapies, and of follow-up reported on specific forms from the departments in question. Descriptive data: From 1977 through 2014, ~110,000 patients are registered in the nationwide, clinical database. The completeness has gradually improved to more than 95%. DBCG has continuously prepared evidence-based guidelines on diagnosis and treatment of breast cancer and conducted quality control studies to ascertain the degree of adherence to the guidelines in the different departments. Conclusion: Utilizing data from the DBCG database, a long array of high-quality DBCG studies of various designs and scope, nationwide or in international collaboration, have contributed to the current updating of the guidelines, and have been an instrumental resource in the improvement of management and prognosis of breast cancer in Denmark. Thus, since the establishment of DBCG, the prognosis in breast cancer has continuously improved with a decrease in 5-year mortality from ~37% to 15%.


  • Open Access

    Socio-demographic, clinical, and health-related factors associated with breast reconstruction – A nationwide cohort study

    by Anne Bodilsen, Søren Christensen, Peer Christiansen, Tine E. Damsgaard, Robert Zachariae, Anders B. Jensen


  • Open Access

    Position paper: Breast cancer screening, diagnosis, and treatment in Denmark

    by Peer Christiansen, Ilse Vejborg, Niels Kroman, Iben Holten, Jens Peter Garne, Peter Vedsted, Susanne Møller, Elsebeth Lynge

    Background. During the last decades the diagnosis, treatment, and prognosis of breast cancer have changed and improved in Denmark. The first mammography screening programme started in 1991. However, for many years only about 20% of Danish women aged 50–69 were offered screening. The national roll-out of screening took place in 2008–2010. Material and methods. Based on published Danish data, this overview describes the status of diagnosis and treatment, and the screening programme. For further evaluating the potential overdiagnosis and overtreatment, additional Danish Breast Cancer Cooperative Group (DBCG) data are included. Results and conclusion. Using incidence-based mortality method, reduction in breast cancer mortality was estimated to be 25% in the target group of women after 10 years of screening in Copenhagen; an outcome comparable to that of randomised controlled trials. A recent Danish study has indicated overdiagnosis to be around 4%. Others have estimated overdiagnosis to be 33%. National DBCG data showed that the rude breast cancer incidence increased during the period 1990–2011 from 126 to 206 per 100 000. The incidence was almost constant for women younger than 50 years. In regions not offering screening, the incidence increased with 3% per year for women aged 50–69 years with similar trends for small and large tumours. After introduction of screening the increase in the age group 50–69 years was confined to small tumours ≤ 20 mm, and most pronounced for node negative patients. From the 1990s, the use of breast conserving surgery has increased from around 25% to 69% in 2010. Screening has not increased the number of mastectomies. Breast cancer treatment in Denmark is evidence based and in agreement with international recommendations. After the introduction of mammography screening the absolute number of patients with a more advanced stage at diagnosis and the absolute number of patients undergoing mastectomy have decreased.


  • Open Access

    Mortality Rates Among Early-Stage Hormone Receptor-Positive Breast Cancer Patients: A Population-Based Cohort Study in Denmark

    by Peer Christiansen, Karsten Bjerre, Bent Ejlertsen, Maj-Britt Jensen, Birgitte B. Rasmussen, A.-V. Laenkholm, Niels Kroman, Marianne Ewertz, Birgitte Offersen, Dorte B. Toftdahl, et al.

    Indications for adjuvant endocrine treatment of breast cancer have gradually increased over the past several years. We aimed to define subgroups of patients who may or may not benefit from adjuvant endocrine therapy. A population-based cohort of systemically untreated breast cancer patients (N = 3197) were identified within the registry of the Danish Breast Cancer Cooperative Group (DBCG). The patients were node negative and had estrogen receptor–positive and/or progesterone receptor–positive tumors (except medullary tumors) and were further characterized by the following risk factors: aged 35–74 years (grouped into 5-year categories) at surgery, tumor size (≤20 mm), and histopathology (grade 1 ductal carcinoma, grade 1 or 2 invasive lobular carcinoma, other or unknown histopathology). Standardized mortality ratios (SMRs) were calculated based on the mortality rate (observed number of deaths per 100 000 person-years) among patients relative to the mortality rate in the general population of women (expected number of deaths per 100 000 person-years). The association between standardized mortality ratio and risk factors were analyzed in univariate and multivariable Poisson regression models. All findings were validated in a subsequent DBCG cohort of breast cancer patients (N = 2710). The median follow-up after surgery was 14.8 years. In the study population there were 970 deaths compared with expected death of 737 women, which was an excess mortality of 233 deaths (SMR = 1.32, 95% CI = 1.24 to 1.40). Mortality rates were 2356 per 100 000 person-years in the study population and 1790 per 100 000 person-years in the general population of women. The mortality rate was associated with larger tumor size (11–20 mm tumors vs 1–10 mm tumors, SMR = 1.42, 95% confidence interval [CI] = 1.31 to 1.53 vs SMR = 1.12, 95% CI = 1.00 to 1.26). The mortality rate was also associated with age (35–59 years, SMR > 1) compared with that in the general population of age-matched women, except for a small subgroup of patients (aged 60–74 years, tumors ≤10 mm, grade 1 ductal carcinoma, and grade 1 or 2 lobular carcinoma: adjusted relative risk = 1.02, 95% CI = 0.89 to 1.16.). A small subgroup of breast cancer patients who were 60 years or older and had hormone-responsive early-stage tumors up to 10 mm, and received no systemic adjuvant therapy, were not at increased risk of mortality compared with women in this age-group in the general population.